Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: EyePoint Pharmaceuticals (EYPT), Charles River Labs (CRL) and Innoviva (INVA)

Tipranks - Tipranks - Fri May 9, 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals (EYPT – Research Report), Charles River Labs (CRL – Research Report) and Innoviva (INVA – Research Report).

Protect Your Portfolio Against Market Uncertainty

EyePoint Pharmaceuticals (EYPT)

Scotiabank analyst Greg Harrison maintained a Buy rating on EyePoint Pharmaceuticals today and set a price target of $18.00. The company’s shares closed last Wednesday at $6.09, close to its 52-week low of $5.54.

According to TipRanks.com, Harrison is a 1-star analyst with an average return of -2.7% and a 43.9% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Vertex Pharmaceuticals, and Rocket Pharmaceuticals. ;'>

EyePoint Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $33.33, a 422.4% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.

See today’s best-performing stocks on TipRanks >>

Charles River Labs (CRL)

J.P. Morgan analyst Casey Woodring maintained a Hold rating on Charles River Labs yesterday and set a price target of $145.00. The company’s shares closed last Wednesday at $136.97.

According to TipRanks.com, Woodring is ranked 0 out of 5 stars with an average return of -8.3% and a 34.6% success rate. Woodring covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Hologic, and Icon. ;'>

Charles River Labs has an analyst consensus of Hold, with a price target consensus of $155.00, representing a 9.9% upside. In a report released yesterday, William Blair also maintained a Hold rating on the stock.

Innoviva (INVA)

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Innoviva, with a price target of $55.00. The company’s shares closed last Wednesday at $18.74.

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -9.0% and a 40.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Edgewise Therapeutics, and Palvella Therapeutics. ;'>

Innoviva has an analyst consensus of Moderate Buy, with a price target consensus of $55.00.

Read More on EYPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).